JAK2 and leukemia: In this study, we found that HSP90 inhibitor (AUY922) in combination with low doses of JAK2 inhibitors (TG101209 or Ruxolitinib) led to the disassembly of the HSP90- HMWNC in IM-resistant leukemia cells and cell death.